Street View: Grail cancer test's progress boosts prospects for multi-cancer detection market

** Cancer test maker Grail GRAL.O received backing from a panel of outside experts advising the US FDA on Wednesday, setting the stage for a potential landmark approval in screening for the disease

** In a 7-2 vote with one abstention, the expert panel concluded that the ability of the test, called Galleri, to catch difficult-to-detect cancers justified its use in adults aged 50 and older

** Shares have climbed over 34% since Monday, after FDA staff briefing documents ahead of the panel meeting identified no concerns regarding analytical performance or safety

OBVIOUS POSITIVE

** Piper Sandler ("Neutral") says it sees the favorable votes across as a "positive for the test Galleri's regulatory path, although the divided effectiveness and benefit-risk votes underscore remaining concerns around clinical benefit"

** Says it expects an FDA decision in H1 2027 and sees federal health insurance coverage as the larger gate to broad adoption

** RBC Capital Markets ("Sector Perform", PT: $84) says the favorable vote is an obvious positive for Grail, and that Galleri's progress is a tailwind for the entire multi-cancer detection (MCD) category

** TD Cowen ("Buy", PT: $88) says the panel's view on Galleri's safety was "stellar" while the view on effectiveness was "a closer call (and biased positive)"

** "The panel seemed to support a broad cancer label, which would include guideline-covered tumors like colorectal cancer and lung (a surprising positive to us) though one with extensive language in the label (about lack of outcomes, false negatives, false positives, etc.)" - Brokerage